Project Grant R01CA297777
Award Date
12/1/24
Completion Date
11/30/28
Dollars Obligated
$696K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60611, USA
Similar Awards
This $895,779 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to advance the science of brain metastases from HER2-positive breast cancer. The key products and services to be delivered under this 7-year grant include: Understanding the fundamental biology and genetic risk factors of HER2-positive breast cancer metastases to the brain through patient tissue-based research. Developing real-time visualization techniques to track cancer cells and...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $230,010 to the University of Chicago to conduct research aimed at unraveling the mechanisms driving metastasis in small cell lung cancer (SCLC). The research strategy integrates human pluripotent stem cell-derived SCLC models, clinical samples, patient-derived xenografts, and advanced technologies like single-cell sequencing to investigate the cellular and molecular...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to the University of Alabama at Birmingham provides $204,295 to integrate advanced molecular imaging techniques to quantify HER2 expression and vascularity in HER2+ breast-to-brain metastasis. The overarching goal is to assess treatment response to radiation following quantification of targeted HER2 bioavailability and heterogeneity. The project aims to: 1) Quantify HER2+...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop a novel therapy with combined immuno- and onco-targeting capabilities to treat triple negative breast cancer. The $661,072 grant, awarded to Northwestern University on January 1, 2025, will fund research to create a first-in-class small molecule inhibitor targeting the USP22 oncogene, which can inhibit cancer cell growth, impair cancer stem cell properties, and boost...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $417,858 to Brigham & Women's Hospital Inc. to develop a novel cellular therapy platform for the treatment of glioblastoma, a highly malignant brain cancer. The project aims to engineer mesenchymal stem cells (MSCs) to release bi-specific T-cell engager (BiTE) molecules targeting multiple tumor antigens (EGFR, EGFRvIII, IL13RA2) and co-express IL-12 and immune checkpoint inhibitors....
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to investigate the role of the protein PlexinB2 in the formation of circulating tumor cell (CTC) clusters and their interaction with immune cells. The $545,983 award to Northwestern University, with a sub-award to Tufts Medical Center, aims to determine the clinical relevance of the PlexinB2 pathway in triple-negative breast cancer, elucidate the molecular mechanisms...
The National Cancer Institute (NCI), under the federal Cancer Biology Research grant program (CFDA 93.396), has awarded a $632,300 Project Grant to Carnegie Mellon University (CMU) to develop an integrated ultra-high-throughput 3D volumetric super-resolution imaging system. This system will combine a multiscale fluorescence mesoscope with magnify expansion microscopy to enable rapid, large-area 3D imaging with exceptional subcellular detail. The goal is to study interactions between cancer and...
This $732,000 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, will support research under the Cancer Treatment Research program. The grant recipient, Northwestern University, will develop a bridge-lipid nanoparticle platform to reprogram immunosuppressive tumor-associated myeloid cells and potentiate radiotherapy for glioblastoma. Over a five-year period, the university will conduct three aims: harnessing myeloid cells to phagocytose...
This Project Grant award for $517,732.00 was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research Federal Grant Program (CFDA 93.395). The grant supports research at the University of Colorado-Denver to investigate how endocrine therapies and radiation therapy can be used in combination to decrease the risk of brain metastases in younger women with aggressive forms of breast cancer. The key objectives are to: 1) determine how endocrine therapies and radiation...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $609,749 to the University of North Carolina at Chapel Hill to develop a novel combination therapy for the treatment of glioblastoma multiforme (GBM), the most aggressive form of brain cancer. The key products/services to be delivered include: Developing an injectable, biodegradable hydrogel scaffold that can accommodate high concentrations of induced neural stem cells...